Children’s National Hospital experts provided a contemporary description of the epidemiology, clinical presentation and management of chronic active Epstein-Barr virus.

Researchers from Children’s National developed a new approach that helped them generate personalized T cells to target and kill tumors.

The study, which included 385 children in the Washington metropolitan area, found a 9.46% SARS-CoV-2 seroprevalence among this group.

Study suggests that patients with antibody deficiency disorders can mount an immune response to SARS-CoV-2 and proposes that vaccination may still be helpful for this population.